

# SCIENTIFIC REPORTS

OPEN

## *In vitro* cytotoxicity activity of novel Schiff base ligand–lanthanide complexes


Kavitha Andiappan<sup>1,2</sup>, Anandhavelu Sanmugam<sup>1</sup>, Easwaramoorthy Deivanayagam<sup>2</sup>, K. Karuppasamy<sup>3</sup>, Hyun-Seok Kim<sup>3</sup> & Dhanasekaran Vikraman<sup>3</sup>

A Schiff base ligand (SBL), N<sup>2</sup>, N<sup>3</sup>-bis (anthracen-9-ylmethylene) pyridine-2, 3-diamine, was synthesized through the condensation of 2,6-diaminopyridine and anthracene-9-carbaldehyde using a 1:2 ratio. <sup>1</sup>H NMR spectra confirmed the observation of non-involvement aromatic carboxylic proton in SBL. A novel series of lanthanide (i.e., praseodymium (Pr), erbium (Er), and ytterbium (Yb))-based SBL metal complexes was successfully synthesized, and their functional groups were elaborately demonstrated using UV–visible, Fourier transform infrared (FT-IR), and fluorescence spectroscopy analyses. FT-IR spectral studies revealed that SBL behaved as a bidentate ligand and it was structured with metal ions by the two azomethine nitrogens. The synthesized SBL-based metal complexes were elaborately performed for cytotoxicity activity versus Vero, human breast cancer (MCF7), and cervical (HeLa) anticancer cell lines.

After the innovative success of cisplatin as a medically recognized antitumor drug, medicinal chemists began interdisciplinary research on metal complexes for interaction with DNA/RNA, biomolecules, and proteins as antitumor drugs<sup>1,2</sup>. On the other hand, the use of platinum (Pt) metal-based cisplatin drug in medicinal purposes causes numerous side effects, which remains a challenge to overcome to prepare efficient anticancer drugs<sup>3–5</sup>. Medicinal inorganic chemistry offers an extensive possibility for the design of novel drugs based on the coordination and redox properties of metal complexes to fight against cancer<sup>6,7</sup>. Currently, various metal complexes, including copper, lanthanum, and ruthenium, complexes, are considered as the most capable replacements for classical cisplatin-type drugs<sup>7–17</sup>.

For decades, Schiff bases have been considered important ligands due to their coordination chemistry, and they can be easily prepared and linked with a different kind of metal ions<sup>18</sup>. Due to the existence of an amine group, analogous to the natural biological systems, Schiff bases show a crucial role in observing the conversion mechanism and racemization reaction in biological systems<sup>19–25</sup>. Schiff bases have been used for various essential biological activities including antitumor, anti HIV, antibacterial, antifertility activities, antimosquito larval, anti-inflammatory, and anticancer<sup>26–33</sup>. Gokhale *et al.*<sup>34</sup> examined the activity of the ligand-based distorted square planar copper(II) complex, cis-[dichloro (N1-(2-benzyloxybenzylidene)pyridine-2-carboxamidrazone) copper(II)], against the human breast cancer cell line MCF-7 using the MTT method. Among the various metal complexes, lanthanide-based metal complexes have been deeply examined owing to their low poisonousness and high biological activities after bonding with ligands. In recent years, the research community has shown great interest in the synthesis of lanthanide-based complexes due to their applicability in DNA interaction and anticancer activity<sup>35–37</sup>. Wang *et al.*<sup>38</sup> have reported a Schiff base La(III) complex prepared from kaempferol and diethylenetriamine interaction with DNA by intercalation mode and observed stronger La(III) complex binding and cleaving capacities with DNA than ligands by *in vitro* cytotoxic behaviors against HepG-2 cell lines and HL-60 cells (the human leukocytoma). Zaho *et al.*<sup>39</sup> have described a La(III) (N,N-bis-(1-carboxy-2-methylpropyl)-1,10-phenanthroline-2,9-dimethanamine) complex for antitumor activity *in vitro* against KB (human nasopharyngeal carcinoma) cells, BGC-823 (human stomach carcinoma) cells, Bel-7402 (human liver carcinoma) cells, HCT-8 (human coloadenocarcinoma) cells, and HL-60 cells. Neelima *et al.*<sup>9</sup> have screened the Schiff base ligand (SBL) and its La(III)

<sup>1</sup>Department of Chemistry (S & H), Vel Tech Multi Tech, Chennai, 600062, India. <sup>2</sup>Department of Chemistry, B.S Abdur Rahman University, Vandalur, Chennai, 600048, India. <sup>3</sup>Division of Electronics and Electrical Engineering, Dongguk University-Seoul, Seoul, 04620, Republic of Korea. Correspondence and requests for materials should be addressed to E.D. (email: [easwar@bsauniv.ac.in](mailto:easwar@bsauniv.ac.in)) or H.-S.K. (email: [hyunseokk@dongguk.edu](mailto:hyunseokk@dongguk.edu)) or D.V. (email: [v.j.dhanasekaran@gmail.com](mailto:v.j.dhanasekaran@gmail.com))



**Figure 1.** Schematic methodology of SBL and its metal complex preparation.


complex, 2,3-dihydro-1*H*-indolo-[2,3-*b*]-phenazin-4(5*H*)-ylidene)benzothiazole-2-amine ( $L^1$ ), for anticancer activity against PC-3 cell lines (human prostate carcinoma) and found the reduction of cell viability of prostate cancer cell lines in a dose-dependent manner.

In the present investigation, a bidentate SBL and its novel lanthanide metal(III) complexes (praseodymium, erbium, and ytterbium) were successfully synthesized by simple one-pot chemical synthesis and plausibly characterized by analytical techniques including UV-visible (UV-vis), Fourier transform infrared (FT-IR), and fluorescence spectroscopy. In addition, their cytotoxicity effects on Vero, HeLa, and MCF7 cancer cell lines *in vitro* were demonstrated in detail.


## Results and Discussion

An SBL,  $N^2, N^3$ -bis (anthracen-9-ylmethylene) pyridine-2, 3-diamine, was synthesized through the condensation of 2,6-diaminopyridine and anthracene-9-carbaldehyde using a 1:2 ratio. The schematic representation of SBL synthesis is given in Fig. 1. Figure S1 (a) shows a  $^1H$  NMR spectrum of the SBL complex that exhibits a specific signal at 12.23 ppm due to NH protons, and the signal in the range of 8.0–8.7 ppm is attributed to azomethine protons. A signal is also observed in the 6.63–8.29 ppm region due to aromatic protons<sup>40,41</sup>. From a  $^{13}C$  NMR spectrum (Figure S1b), SBL exhibits a specific signal at 165.37 ppm due to azomethine carbon<sup>42,43</sup>. It also shows a signal in the range of 126–132 ppm that corresponds to the aromatic carbons<sup>44,45</sup>. The observed NMR results confirmed the successful formation of the SBL complex. Further, a novel series of lanthanide (i.e., praseodymium (Pr), erbium (Er) and ytterbium (Yb))-based SBL metal complexes was successfully synthesized by simple one-pot chemical synthesis. The detailed experimental procedures used to prepare the SBL-based metal complexes are elaborated in the experimental part. The preparation scheme for the Schiff base ligand-Pr (SBLPr), Schiff base ligand-Er (SBLEr), and Schiff base ligand-Yb (SBLYb) metal complexes is shown in Fig. 1.

**Functional properties analyses of SBL and its metal complexes.** Electronic spectral studies are important tools to identify the structure of ligands and their metal complexes, and they are also used for examining the stereochemistry of metal ions in the complexes based on their peak locations and the digit of d-d transition peaks. The UV-vis spectra of the SBL and its metal complexes (i.e., SBLPr, SBLEr, and SBLYb) were recorded at room temperature using methanol as the solvent. Figure 2 shows the UV-vis electronic spectra for the SBL and its metal complexes. The UV-vis spectra of the SBL revealed two strong absorption bands of intra-ligand charge transfer transition at 276 and 313 nm, which can be attributed to the  $\pi$ - $\pi^*$  transition and  $n$ - $\pi^*$  transitions of the carbonyl group of anthracene-9-carbaldehyde, respectively, and a slight shift for SBLEr and SBLYb, except SBLPr, metal complexes. In addition, the electronic absorption spectra of metal complexes, such as SBLPr, SBLEr, and SBLYb, revealed a broad band in the region between 420 and 480 nm, particularly at 442, 445, and 450 nm, respectively. These bands are attributed to  $^2B_{1g} \rightarrow ^2A_{1g}$  transition, which is characteristic of the distorted square planar geometry of Pr, Er, and Yb ions. The band positions of the absorption maxima, band assignments, and geometry of the complexes are tabulated in supporting information Table S1. The obtained results are in agreement with earlier results<sup>46,47</sup>.




**Figure 2.** UV-vis spectra of SBL and its metal complexes in range of 250–800 nm.



**Figure 3.** FT-IR spectra of SBL and its metal complexes. (a) Azomethine group ( $\nu_{\text{HC=N}}$ ) region, (b) -M-N- region, and (c) Pyridine ring N- region.

To identify the bonding mode as well as the complexation behavior of the prepared SBL and its metal complexes, the FT-IR spectral characteristics were recorded for SBL and its metal complexes. For 2,3-diaminopyridine, the characteristic vibrational peaks were reported at 3390, 3309, 2883, 1637, 1577, 1184, 1120, and 1064  $\text{cm}^{-1}$  corresponding to N-H asymmetric stretching, N-H symmetric stretching, C-H aromatic symmetric stretching, N-H stretching of the pyridine ring, C=C stretching, C-N stretching, C-H in-plane bending, and C-O stretching, respectively<sup>48</sup>. Moreover, the anthracene-9-carbaldehyde characteristic vibrational peaks were reported at 2924–2854, 1682, and 1120  $\text{cm}^{-1}$  corresponding to aromatic C-H stretching, C=O stretching, and C=C aromatic ring stretching, respectively. The FT-IR spectra of the SBL and its metal complexes are displayed in Fig. 3. The formation of the SBL is confirmed by the presence of a strong absorption band at 1608  $\text{cm}^{-1}$ , which represents the azomethine group ( $\nu_{\text{HC=N}}$ ), as shown in Fig. 3(a). The addition of metal nitrate salts to the SBL affects the structural organization of metal complexes and shifts the wavenumber regions toward higher wavenumbers<sup>49,50</sup>. For instance, the absorption bands of the metal complexes, SBLPr, SBLEr, and SBLYb, are shifted to higher wavenumbers than those of the SBL (i.e., 1661, 1660, and 1662  $\text{cm}^{-1}$ , respectively) in the spectra. This suggests that the azomethine nitrogen of SBL is involved in chelation (Fig. 3a) and hence that complexation takes place through the N-atom of the azomethine group. The coordination between the metal ion and N-atom of the azomethine group is further confirmed by analyzing the FT-IR spectra in the region between 520 and 400  $\text{cm}^{-1}$ . In this region, the FT-IR spectra of all the metal complexes show strong bands, which may be due to M-N symmetric and asymmetric stretching vibrations, as shown in Fig. 3(b). In addition, it is important to note that no significant changes are observed in the wavenumber region 550–480  $\text{cm}^{-1}$ , which indicates that the pyridine ring N-atom does not participate in binding or chelation with metal ions, as shown in Fig. 3(c). Correspondingly, all the prepared metal complexes (SBLPr, SBLEr, and SBLYb) show vibrational bands in the region between 1110 and 1120  $\text{cm}^{-1}$ , which corresponds to phenyl ring vibrations<sup>51</sup>. The other important vibrational peaks and their corresponding




**Figure 4.** Fluorescence spectra of SBL metal complexes (Inset: fluorescence spectrum of SBL). The deconvoluted spectra included for SBLEr and SBLPr metal complexes were due to their combined broad spectral peak.

assignments are tabulated in supporting information Table S2. The molar conductance study was carried out using di-methyl sulfoxide (DMSO) as a solvent and their values are tabulated in supporting information Table S3. The observed values ( $100\text{--}128\text{ ohm}^{-1}\text{ cm}^2\text{ mol}^{-1}$ ) for the metal complexes indicates that the synthesized complexes are in electrolytic nature with M(III) ions and the nitrate ions are proposed to be present in the outside of coordination sphere. The observed results are in greatly concurrent with the earlier reports<sup>52</sup>.

Synthesized metal complexes have excellent fluorescence behavior in nature, and their emission spectra were recorded at a 300-nm excitation wavelength. The SBL shows an intense peak at 369 nm and a weaker broad peak at 495 nm, which are attributed due to the  $\pi\text{--}\pi^*$  transition, as shown in the inset of Fig. 4. For the SBLPr metal complex, a combined emission band of SBL is observed in the range of 380–490 nm due to the  $\pi\text{--}\pi^*$  transition, which is displayed with its deconvoluted peaks, as shown in Fig. 4. The SBL peak broadening is increased with a higher wavelength shift due to the complex formation of Pr with SBL. For Pr, a sharp peak is observed at 736.5 nm in the SBLPr spectrum. In the case of the SBLYb complex, a sharp SBL peak is observed at 495 nm with a shoulder peak at 408 nm. A low-intensity broad peak is exhibited at 735.4 nm due to the fluorescence behavior of Yb. For the SBLEr metal complex, a combined emission band of SBL is observed in the range of 385–580 nm with a broad peak at 733.5 nm of Er, showing behavior similar to that of the SBLPr complex, as shown in Fig. 4. The fluorescence curves indicate that energy is transferred more efficiently from the lowest triplet state energy level ( $T_1$ ) of the ligand to the rare earth lowest resonance energy level ( $5D_4$ )<sup>53</sup>. In an earlier report, a blue shift in the lanthanum(III) complex indicated the lanthanum ions have influenced the energy absorption of the complex system by the coordination with ligand<sup>54,55</sup>.

Thermal stability as well as decomposition mechanisms for our SBL and its complexes of SBLEr, SBLPr, and SBLYb were analyzed by TG-DTG measurements under an inert atmosphere. According to the coordination chemistry, the inclusion of metal ions and alteration of the ligand's functional groups could lead to thermal instability and alter its corresponding decomposition stages<sup>56</sup>. This investigation also demonstrated the thermal stability of SBL changes by the inclusion of rare earth metal ions in the SBL matrix. The precursor materials, such as 2,3-diaminopyridine (DAP) and anthracene-9-carbaldehyde, showed one-step and two-step thermal decomposition with Td values of 287 and 368 °C, respectively, as reported earlier<sup>57,58</sup>. Figure 5(a) represents the thermograms of the SBL and the SBLEr, SBLPr, and SBLYb complexes. From the thermogram, the SBL shows two weight-loss stages. The earlier stage is ascribed to the decomposition of 2,3-diaminopyridine molecules, and the later stage is ascribed to the decomposition of anthracene-9-carbaldehyde. The residues obtained at 750 °C may be a carbon residue. Further, the mass loss happens at lower temperatures (237–345 °C) than that of precursor DAP, which indicates that the SBL is weaker than DAP. This may be due to the reduction in the number of primary amino groups of DAP after SBL formation. These results are in line with earlier reports<sup>59–61</sup>. Moreover, the TG



**Figure 5.** (a) TG and (b) DTA curves of SBL and its metal complexes.


curves of SBLPr, SBLYb, and SBLEr are exhibited with four-step degradation stages. The initial stage is due to the loss of physically adsorbed water molecules. The second stage is ascribed to the loss of free amino pyridine units. The third step is assigned to the deformation of the coordination bond between the azomethine nitrogen and metal ion and the decomposition of the condensed pyridine unit. The final step is attributed to the decomposition of anthracene carbaldehyde units. In addition, it is noticed from the thermogram that the thermal stability of the metal complexes seems to be lower than that of the SBL. This is due to the formation of thermally stable metal oxides, which results in the larger amount of residue weight loss in the complexes as compared to the SBL. The maximum amount of mass loss observed at higher temperatures in SBLYb than in the other complexes, which represents the ytterbium complex has better thermal stability compared with the erbium and praseodymium complexes<sup>62,63</sup>. The DTG curves of the SBL and its corresponding metal complexes are displayed in Fig. 5(b). The DTG curves of both the SBL and metal complexes suggest that thermal decay always involved exothermic decomposition. The endothermic peak positions are diverse for the SBL and its metal complexes which might be due to the difference in the complexation behavior between metal ions. The different weight losses of the SBL and its corresponding metal complexes obtained from TG-DTG analysis are tabulated in supporting information Table S4. The SEM micrographs of the SBL and its metal complexes (SBLPr, SBLEr, and SBLYb) are presented in Fig. 6 (a–d). The larger particles are formed by agglomeration, as predicted by morphological structure.

### Cytotoxicity behavior against Vero, MCF7, and HeLa cancer cell lines using SBLPr and SBLEr metal complexes.

SBL-based metal complexes (SBLPr and SBLEr) are to be useful as anticancer drugs because of their stability, cytocompatibility, and flexible binding with biomolecules<sup>64</sup>. In recent times, the advancement of drug-delivery systems has been broadly attempted to produce the anticipated healing effect in patients with low opposing reactions<sup>65</sup>. In this work, the antiproliferative actions of SBLPr and SBLEr were examined in three different cancer cell lines (i.e., Vero, HeLa, and MCF7 cells) and evaluated by MTT assay.

Observations of the effect of synthesized SBLPr and SBLEr at different concentrations (i.e., 5, 10, 25, 50, 75, and 100  $\mu\text{g/ml}$  complexes) on cell viability of Vero, MCF7, and HeLa cells were made at 24 h. The observed results explicated the cells' viability at 85–90% for the concentrations up to 5  $\mu\text{g/ml}$ , as shown in Fig. 7(a,b). As shown in Fig. 7, SBLPr and SBLEr efficiently induced apoptosis in Vero, MCF7, and HeLa cells in a dosage dependent manner. The SBLPr-tested Vero cells displayed a good biocompatibility compared to the complex of SBLEr, as shown in Fig. 7. The effective decrements in cell viability were noted in treated concentrations when compared to control cells. An earlier report revealed that the Vero cell lines at higher metal complex concentrations exposed substantial cell death<sup>66,67</sup>. Moreover, the biocompatibility characteristics of gold nanoparticles (AuNPs) were eventually performed versus Vero, HeLa, MCF7 and HeP-G2 cell lines<sup>68</sup>. The Vero cells treated for 24 h with the respective  $\text{IC}_{50}$  concentration of SBLPr and SBLEr became rounded and began to shrink and lose their interaction with nearby cells. The morphological images shown in Fig. 8(a–c) confirmed the toxic effect of SBLPr and SBLEr (@25  $\mu\text{g/ml}$ ) samples against Vero cells compared with control cells.

For MCF7 and HeLa cells, the microscopic images of control cells and cells treated with 25  $\mu\text{g/ml}$  SBLPr and SBLEr for 24 h are provided in Fig. 8(d–i). The MCF7 cells (Fig. 8d) consisted of irregular confluent combines with smooth-edged polygonal structures. The cells showed numerous cell surface protuberances. Under the controlled conditions, the untreated cancer cell lines (HeLa and MCF7) grew well with obvious skeletons. The cells appeared in a circular shape under an inverted microscope. After treatment with 25  $\mu\text{g/ml}$  of SBLPr and SBLEr for 24 h, the cell volume was reduced and the cell density was decreased, as shown in Fig. 8. For the metal complex-treated cells, the metal (Pr) and (Er) ions from SBLPr and SBLEr, respectively, cooperated with phosphorus moieties in DNA, causing to control the DNA reproduction, which resulted in the loss of cell viability and cell death<sup>54,69</sup>. It has been validated that SBLPr and SBLEr are active metal complexes against human cancer cell lines<sup>55,62</sup>. Omar *et al.*<sup>41</sup> have described the different concentrations of metal nanoparticles for cytotoxicity effects on MCF7 and HepG2 cancer cell lines. Likewise, Mohanan *et al.* have demonstrated the cytotoxicity behavior of crocin–metal nanoparticles against MCF7 cells after 24 and 48 h growth<sup>40</sup>. The observed results from the present study against MCF7 and HeLa cell lines treated with SBLPr and SBLEr (at 25  $\mu\text{g/ml}$ ) revealed cell death up to ~49% and ~42–51%, respectively. The cells treated with SBLPr and SBLEr underwent cell shrinkage, which is evidenced from Fig. 8. Moreover, our synthesized metal complexes showed better inhibition properties against




**Figure 6.** SEM micrographs of (a) SBL and (b) SBLPr, (c) SBLEr, and (d) SBLYb complexes.


MCF7 cancer cell lines. In addition, they showed that apoptotic bodies lead to cell death, as proved by variations such as restriction of cell growth, cytoplasmic condensation, and loss of membrane integrity<sup>70</sup>.

**Analyses of DNA fragmentation and apoptosis against MCF7 and HeLa cancer cell lines using SBLPr and SBLEr metal complexes.** DNA fragmentation is extensively assumed a distinctive of apoptosis<sup>68,71</sup>. The initiation of apoptosis may be established by irregular deficiency in cell size, in which the cells are condensed, and DNA fragmentation<sup>72</sup>. The observation of oligonucleosomal-shaped rubbles from the chromosomal DNA cleavage in is a primary part of apoptosis. Sophisticated biochemistry work has recognized the fragmentation factor of DNA leading apoptotic endonucleases in the destruction of DNA *in vitro*. Numerous reports are available on the capability of metal complexes for catalyzing the cleavage of DNA<sup>70</sup>. We therefore examined DNA-cleaving activities by an electrophoresis assay using SBLPr and SBLEr complex-examined MCF7 and HeLa cells. In the present study, HeLa and MCF7 IC<sub>50</sub> cells were treated with SBLPr and SBLEr for 24 h, showing a decrease in cell survival by including DNA fragmentation. Figure 9(a,b) indicates the induction of apoptosis in the intermediary smears. The full-length electrophoresis images are presented in Supplementary Figure S2. For comparison, untreated control chambers are provided to explore the observation of no DNA fragmentation.


Most of the small-molecule anticancer drugs employ their cytotoxic effects via apoptosis, which is monitored by the acridine orange (AO)/ethidium bromide (EB) dual staining method. As shown in Fig. 10, SBLPr and SBLEr efficiently induced apoptosis in MCF7 and HeLa cells. Apoptosis is commonly characterized by different morphological features, such as nuclear fragmentation, chromatin condensation, or the formation of apoptotic bodies<sup>73,74</sup>. To gain more evidence of the induction of apoptotic cell death by the SBLPr and SBLEr complexes, the apoptosis-inducing properties of MCF7 and HeLa cells were further examined by fluorescence microscopy using propidium iodide (PI) staining. In the case of MCF7 and HeLa IC<sub>50</sub> cells treated with SBLPr and SBLEr, at 24 h, they displayed a progressive growth in the number of PI-positive cells. As shown in Fig. 11, nuclear fragmentation, chromatin condensation, and the formation of apoptotic bodies occurred following the treatment of MCF7 and HeLa cells with 25 μg/mL SBLPr and SBLEr complexes for 24 h. The results of the cell cycle and apoptosis experiments demonstrate that SBLPr and SBLEr complexes can effectively induce DNA damage and thus lead to cell cycle arrest and apoptosis in MCF7 and HeLa cells. Similarly, in an earlier study, curcumin- or catechin-examined different cell lines (HCT15, HCT116, and HepG2) showed the enrichment of condensed nuclear morphology, chromatin fluorescence, and the existence of dead cells<sup>43</sup>. This suggests that SBLPr and SBLEr metal complexes are stimulated the cell death in MCF7 and HeLa cells by the reactive oxygen species (ROS)-imposed apoptotic process. The enrichment of ROS levels and consequent damage of mitochondria membrane potency could be enhanced the cell death effectively.




**Figure 7.** Cell viability of cancer cell lines (i.e., MCF7, HeLa, and Vero) against (a) SBLPr and (b) SBLEr metal complexes.



**Figure 8.** Morphological changes induced by SBLPr and SBLEr metal complexes using 25 µg/ml compared with control cancer cell lines.



**Figure 9.** (a) DNA fragmentation of MCF7 and HeLa IC<sub>50</sub> cells treated with SBLPr complex at 24 h. Lane 1: 1 kb DNA ladder, Lane 2: MCF7 control DNA, Lane 3: SBLPr-treated MCF7 cell (25 µg/ml), Lane 4: SBLPr-treated HeLa cell (25 µg/ml), Lane 5: HeLa control DNA. (b) DNA fragmentation of MCF7 and HeLa IC<sub>50</sub> cells treated with SBLEr complex at 24 h. Lane 1: 1 kb DNA ladder, Lane 2: MCF7 control DNA, Lane 3: SBLEr-treated MCF7 cell (25 µg/ml), Lane 4: HeLa control DNA, Lane 5: SBLEr-treated HeLa cell (25 µg/ml).




**Figure 10.** Morphological variations of AO/EB double-stained MCF7 and HeLa cells and their SBLPr- and SBLEr-treated cells using 25 µg/ml for 24 h.

## Conclusion

The development of an intense method to synthesize an SBL and its novel lanthanide metal complexes was demonstrated by simple one-pot chemical synthesis. The FT-IR spectral studies revealed that the SBL performed as a neutral bidentate ligand and it was bound with metal ions via the two azomethine nitrogens. In the electrophoresis experiments, SBLPr and SBLEr complexes were found to cause significant DNA cleavage of MCF7 and HeLa cells. In MTT assay cytotoxicity studies, SBLPr and SBLEr complexes exhibited anticancer activity against Vero, MCF7, and HeLa cancer cells. From the results of AO/EB staining assay, SBLPr and SBLEr complexes induced the apoptosis of MCF7 and HeLa cells. The PI staining assay showed that SBLPr and SBLEr complexes indeed induced DNA fragmentation, which provides additional confirmation of apoptosis. We hope that the observed results clearly demonstrate the cytotoxicity effects of SBLPr and SBLEr complexes against human cancer cell lines and that they become novel antitumor agents for humans.





**Figure 11.** Morphological variations of PI-stained MCF7 and HeLa cells after treated with SBLPr and SBLEr using 25 µg/ml for 24 h.

## Experimental Details

**Synthesis of SBLs.** A 2,3-diaminopyridine (10 mmol) solution was mixed with a 9-anthraldehyde (10 mmol) solution in a 1:2 molar ratio in methanol medium. The mixed solution was continuously stirred using magnetic stirrer for 2 h at 80 °C. Then, it was allowed to cool to room temperature, and the yellowish-orange crystalline product was separated out. It was then washed with ice-cold methanol and dried. The purity of the compound was examined with thin-layer chromatography. The collected yield was as high as 80%.

**Synthesis of lanthanide–SBL complexes.** The lanthanide–SBL complexes were synthesized as per the following standard procedure. The SBL (0.2 mmol) was dissolved in methanol. Then, 0.1 mmol of praseodymium nitrate as a source for lanthanide was slowly added to the above solution. The reaction mixture was refluxed in an oil bath at 80 °C for 4 h. After the specific period, the solution was allowed to cool gradually, and the SBL metal complex was collected in the liquid phase. Then, it was filtered using Whatman filter paper. The collected SBL metal complex was washed with diethyl ether and dried in a vacuum oven. The same procedure was repeated using erbium nitrate and ytterbium nitrate instead of praseodymium nitrate to prepare the Yb- and Er-based SBL complexes. The crude precipitate of [Pr (Er or Yb) (NO<sub>3</sub>)<sub>2</sub>(H<sub>2</sub>O)], NO<sub>3</sub> was purified from the acetonitrile-methanol mixture.

**Anticancer activities of SBL–lanthanide complexes.** *Cell culture.* All the cancer cell lines such as Vero, MCF7 (breast cancer), and HeLa (cervical cancer) were purchased from the National Centre for Cell Sciences (NCCS), Pune, India. The purchased cells were preserved in the logarithmic level of growth in DMEM medium accompanied with 10% (v/v) heat-inactivated fetal bovine serum, 100 µg/mL penicillin, and 100 µg/mL streptomycin. Then, the samples were preserved at 37 °C in a 5% CO<sub>2</sub>–95% air humidified incubator. The cytotoxic effects of the SBL and its Pr and Er complexes were tested against cancer cell lines (i.e., Vero, MCF7, and HeLa) by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay)<sup>75</sup>.

*Cytotoxicity analysis against cancer cell lines.* The sustainable Vero, HeLa, and MCF7 cells were individually grown in 96-well microplates (1 × 10<sup>6</sup> cells/mL) and incubated at 37 °C for 24 h with a 5% CO<sub>2</sub> incubator to allow them to develop to 90% confluence. Thereafter, the medium was exchanged, and the Vero cells were examined with SBLPr and SBLEr at various concentrations of 5, 10, 25, 50, 75, and 100 µg/mL. Then, the samples were incubated for 24 h. The samples were take-out from the incubator and washed with phosphate-buffered saline (PBS, pH- 7.4). Then, 20 µL of MTT solution (5 mg/mL) was mixed to each well, and they were performed to stand at 37 °C in the dark for an extra 4 h. Then, 100 µL of DMSO was added, and the formazan crystals were dissolved. The absorbance was measured spectrometrically at 570 nm using an ELISA plate reader. The percentage of cell viability was estimated as follows:

$$\text{Cell viability(\%)} = (\text{Absorbance of treated cells} / \text{Absorbance of control cells}) \times 100 \quad (1)$$

The 50% of inhibited cell growth was denoted as the IC<sub>50</sub> value, which was used as a parameter for the cytotoxicity study. The morphological changes of untreated (control) and examined IC<sub>50</sub> cells were observed after 24 h under a bright field microscope. The cytotoxicity results were received from three independent measurements by different cell passages for all the cancer cell lines, although each measurement was implemented in triplicate.

**Assessment of apoptosis.** HeLa and MCF7 cells were separately plated at a density of  $5 \times 10^4$  cells/well into a 6-well chamber plate. At >90% confluence, the cells were treated with SBLPr and SBLer complexes for 24 h. The cells were washed with PBS fixed in methanol: acetic acid (3:1, v/v) for 10 min and stained with  $50 \mu\text{g/mL}$  PI for 20 min. For the nuclear analysis, the cell plates were washed with PBS and stained with  $5 \mu\text{L}$  of AO ( $100 \mu\text{g/mL}$ ) and  $5 \mu\text{L}$  of EB ( $100 \mu\text{g/mL}$ ). The morphological variations in the stained cells, including apoptotic nuclei (condensed chromatin, fragmented nuclei, and intensely stained), were perceived by fluorescence microscopy. Further, electrophoresis analysis were carried out for HeLa and MCF7 cell lines using a gel tank consisted of ethidium bromide with one percentage of agarose gel at 1 hour in 90 V by reported method<sup>68,76</sup>.

**Characterization.** The synthesized SBL and its rare earth metal complexes were characterized by UV-vis spectroscopy using a Perkin Elmer LS25 spectrophotometer with methanol as a solvent. FT-IR analyses were carried out using a JASCO spectrophotometer. The  $^1\text{H}$  NMR spectrum was recorded using a Bruker Advance DPZ-300 spectrometer operating at 300 MHz using DMSO (spectroscopic grade) as a solvent and TMS as an internal standard. The surface morphology of SBL and its metal complexes was analyzed by FESEM (FEI Quanta 250 Czech Republic). Fluorescence spectra were measured by using a Perkin Elmer LS45 fluorescence spectrophotometer. The thermal analysis was performed on a PCT-2A thermo balance analyzer operating at a heating rate of  $10^\circ\text{C}/\text{min}$  in the range of ambient temperature to  $720^\circ\text{C}$  under  $\text{N}_2$ . The molar conductance study was carried out using conductivity meter instrument (model CM Elico-185) with 1 mM DMSO as a solvent at room temperature.

## References

- Johnstone, T. C., Suntharalingam, K. & Lippard, S. J. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. *Chem. Rev.* **116**, 3436–3486 (2016).
- Woolins, J. D., Woolins, A. & Rosenberg, B. The detection of trace amounts of trans-Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> in the presence of cis-Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>. A high performance liquid chromatographic application of kurnakow's test. *Polyhedron* **2**, 175–178 (1983).
- Levi, J. A., Aroney, R. S. & Dalley, D. N. Haemolytic anaemia after cisplatin treatment. *Br. Med. J.* **282**, 2003–2004 (1981).
- Fuertes, M. A., Alonso, C. & Pérez, J. M. Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance. *Chem. Rev.* **103**, 645–662 (2003).
- Kathiresan, S., Muges, S., Annaraj, J. & Murugan, M. Mixed-ligand copper(II) Schiff base complexes: the vital role of co-ligands in DNA/protein interactions and cytotoxicity. *New J. Chem.* **41**, 1267–1283 (2017).
- Dai, Y., Wang, Y.-G., Geng, J., Peng, Y.-X. & Huang, W. Dinuclear Cu(II) complexes based on two flexible Schiff-base ligands and one unusual *in situ* formed diphenolate 2, 6-piperidin-4-one derivative. *Dalton Trans.* **43**, 13831–13834 (2014).
- Notaro, A. & Gasser, G. Monomeric and dimeric coordinatively saturated and substitutionally inert Ru(II) polypyridyl complexes as anticancer drug candidates. *Chem. Soc. Rev.* (2017).
- Hu, K., Li, F., Zhang, Z. & Liang, F. Synthesis of two potential anticancer copper(II) complex drugs: their crystal structure, human serum albumin/DNA binding and anticancer mechanism. *New J. Chem.* **41**, 2062–2072 (2017).
- Neelima, P. K., Siddiqui, S., Arshad, M. & Kumar, D. *In vitro* anticancer activities of Schiff base and its lanthanum complex. *Spectrochim. Acta A* **155**, 146–154 (2016).
- Usman, M. *et al.* Coumarin centered copper(II) complex with appended-imidazole as cancer chemotherapeutic agents against lung cancer: molecular insight via DFT-based vibrational analysis. *RSC Adv.* **7**, 36056–36071 (2017).
- Smirnov, A. S. *et al.* Conformational stabilization of isatin Schiff bases—biologically active chemical probes. *RSC Adv.* **7**, 10070–10073 (2017).
- Lu, C., Laws, K., Eskandari, A. & Suntharalingam, K. A reactive oxygen species-generating, cyclooxygenase-2 inhibiting, cancer stem cell-potent tetranuclear copper(II) cluster. *Dalton Trans.* (2017).
- Zeng, L. *et al.* The development of anticancer ruthenium (II) complexes: from single molecule compounds to nanomaterials. *Chem. Soc. Rev.* (2017).
- Ronconi, L. & Sadler, P. J. Using coordination chemistry to design new medicines. *Coord. Chem. Rev.* **251**, 1633–1648 (2007).
- Brujininx, P. C. & Sadler, P. J. New trends for metal complexes with anticancer activity. *Curr. Opin. Chem. Biol.* **12**, 197–206 (2008).
- Rajarajeswari, C. *et al.* Copper(II) complexes with 2NO and 3N donor ligands: synthesis, structures and chemical nuclease and anticancer activities. *Dalton Trans.* **42**, 8347–8363 (2013).
- Wang, D. & Lippard, S. J. Cellular processing of platinum anticancer drugs. *Nat. Rev. Drug Discov.* **4**, 307 (2005).
- Keypour, H. *et al.* Synthesis, spectral characterization, structural investigation and antimicrobial studies of mononuclear Cu(II), Ni(II), Co(II), Zn(II) and Cd(II) complexes of a new potentially hexadentate N<sub>2</sub>O<sub>4</sub> Schiff base ligand derived from salicylaldehyde. *J. Mol. Struct.* **1032**, 62–68 (2013).
- Yan, X. *et al.* Proteasome inhibition and cytostatic effects on human cancer cells by pyrazolone-enamines: a combined crystallographic, structural and computational study. *New J. Chem.* **39**, 2168–2180 (2015).
- Delgado, S., Santana, A., Castillo, O. & Zamora, F. Dynamic combinatorial chemistry in a solvothermal process of Cu(I, II) and organosulfur ligands. *Dalton Trans.* **39**, 2280–2287 (2010).
- Morschhäuser, R. *et al.* Microwave-assisted continuous flow synthesis on industrial scale. *Green Process. Synth.* **1**, 281–290 (2012).
- Baghibanzadeh, M., Pilger, C. & Kappe, C. O. Rapid Nickel-Catalyzed Suzuki–Miyaura Cross-Couplings of Aryl Carbamates and Sulfamates Utilizing Microwave Heating. *J. Org. Chem.* **76**, 1507–1510 (2011).
- Wang, J., Qiao, L., Li, S. & Yang, G. Protective effect of ginsenoside Rb1 against lung injury induced by intestinal ischemia-reperfusion in rats. *Molecules* **18**, 1214–1226 (2013).
- Mishra, N. & Kumar, D. Coordination chemistry of Schiff base tin complexes. *Russ. J. Coord. Chem.* **40**, 343–357 (2014).
- Evans, C. in *Biochemistry of the Lanthanides* 285–337 (Springer, 1990).
- Baseer, M. A., Jadhav, V. D., Phule, R. M., Archana, Y. V. & Vibhute, Y. B. Synthesis and Antibacterial Activity of Some New Schiff Bases. *Orient J. Chem.* **16**, 553–556 (2000).
- Sridhar, S., Pandeya, S. & De Clercq, E. Synthesis and anti-HIV activity of some isatin derivatives. *Boll. Chim. Farm.* **140**, 302–305 (2000).
- Singh, W. M. & Dash, B. C. Synthesis of some new Schiff bases containing thiazole and oxazole nuclei and their fungicidal activity. *Pesticides* **22**, 33–37 (1988).
- Guofa, L., Tongshun, S. & Yongnian, Z. Infrared and Raman spectra of complexes about rare earth nitrate with Schiff base from o-vanillin and 1-naphthylamine. *J. Mol. Struct.* **412**, 75–81 (1997).
- Das, B. P., Choudhury, T. R., Das, G. K., Chowdhury, D. N. & Choudhury, B. Comparative Studies on Larcicidal Activity of some Schiff Bases with Corresponding Amines. *Chem. Environ. Res.* **3**, 19–23 (1994).
- Sparatore, F., Pirisino, G., Alamanni, M., Manca-Dimich, P. & Satta, M. Azomethine derivatives with anti-inflammatory activity. *Boll. Chim. Farm.* **117**, 638–651 (1978).

32. Chaviara, A. T. *et al.* *In vivo* anticancer, anti-inflammatory, and toxicity studies of mixed-ligand Cu(II) complexes of dien and its Schiff dibases with heterocyclic aldehydes and 2-amino-2-thiazoline. Crystal structure of [Cu (dien)(Br)(2a-2tzn)](Br)(H<sub>2</sub>O). *J. Inorg. Biochem.* **99**, 2102–2109 (2005).
33. Fahmi, N., Shrivastava, S., Meena, R., Joshi, S. & Singh, R. Microwave assisted synthesis, spectroscopic characterization and biological aspects of some new chromium(III) complexes derived from NA O donor Schiff bases. *New J. Chem.* **37**, 1445–1453 (2013).
34. Gokhale, N. *et al.* The crystal structure of first copper(II) complex of a pyridine-2-carboxamidrazone—a potential antitumor agent. *Inorg. Chem. Commun.* **4**, 26–29 (2001).
35. Biba, F. *et al.* New Insights into the Chemistry of the Antineoplastic Lanthanum Complex Tris (1, 10-phenanthroline) tris (thiocyanato-κN) lanthanum(III)(KP772) and Its Interaction with Biomolecules. *Eur. J. Inorg. Chem.* **2009**, 4282–4287 (2009).
36. Kostova, I. & Momkov, G. New cerium(III) complexes of coumarins—Synthesis, characterization and cytotoxicity evaluation. *Eur. J. Med. Chem.* **43**, 178–188 (2008).
37. Chen, G.-J. *et al.* Synthesis, DNA binding, photo-induced DNA cleavage and cell cytotoxicity studies of a family of light rare earth complexes. *J. Inorg. Biochem.* **109**, 90–96 (2012).
38. Wang, Z.-M., Lin, H.-K., Zhu, S.-R., Liu, T.-F. & Chen, Y.-T. Spectroscopy, cytotoxicity and DNA-binding of the lanthanum(III) complex of an l-valine derivative of 1,10-phenanthroline. *J. Inorg. Biochem.* **89**, 97–106 (2002).
39. Zhao, G., Li, F., Lin, H. & Lin, H. Synthesis, characterization and biological activity of complexes of lanthanum(III) with 2-(1'-phenyl-2'-carboxyl-3'-aza-n-butyl)-1,10-phenanthroline and 2-(1'-p-phenol-2'-carboxyl-3'-aza-n-butyl)-1,10-phenanthroline. *Bioorgan. Med. Chem.* **15**, 533–540 (2007).
40. Mohanan, K., Athira, C., Sindhu, Y. & Sujamol, M. Synthesis, spectroscopic characterization and thermal studies of some lanthanide(III) nitrate complexes with a hydrazo derivative of 4-aminoantipyrine. *J. Rare Earths* **27**, 705–710 (2009).
41. Omar, M. M., Mohamed, G. G. & Ibrahim, A. A. Spectroscopic characterization of metal complexes of novel Schiff base. Synthesis, thermal and biological activity studies. *Spectrochim. Acta A* **73**, 358–369 (2009).
42. Felicio, R., Cavalheiro, E. & Dockal, E. Preparation, characterization and thermogravimetric studies of [N, N'-cis-1, 2-cyclohexylene bis (salicylideneaminato)] cobalt(II) and [N, N'-(±)-trans-1, 2-cyclo-hexylene bis (salicylideneaminato)] cobalt(II). *Polyhedron* **20**, 261–268 (2001).
43. Mallick, K., Witcomb, M. J. & Scurrell, M. S. *In situ* synthesis of copper nanoparticles and poly (o-toluidine): a metal–polymer composite material. *Eur. Polym. J.* **42**, 670–675 (2006).
44. Pavitha, P. *et al.* Synthesis, structural, spectroscopic, anti-cancer and molecular docking studies on novel 2-[(Anthracene-9-ylmethylene)amino]-2-methylpropane-1,3-diol using XRD, FTIR, NMR, UV–Vis spectra and DFT. *J. Mol. Struct.* **1147**, 406–426 (2017).
45. Arjunan, V., Ravindran, P., Rani, T. & Mohan, S. FTIR, FT-Raman, FT-NMR, ab initio and DFT electronic structure investigation on 8-chloroquinoline and 8-nitroquinoline. *J. Mol. Struct.* **988**, 91–101 (2011).
46. Nagashri, K., Joseph, J. & Dhanaraj, C. J. Copper(II) complexes of hydroxyflavone derivatives as potential bioactive molecule to combat antioxidants: synthesis, characterization and pharmacological activities. *Appl. Organomet. Chem.* **25**, 704–717 (2011).
47. Joseph, J., Nagashri, K. & Rani, G. A. B. Synthesis, characterization and antimicrobial activities of copper complexes derived from 4-aminoantipyrine derivatives. *J. Saudi Chem. Soc* **17**, 285–294 (2013).
48. Karpagam, J., Sundaraganesan, N., Kalaichelvan, S. & Sebastian, S. Anharmonic vibrational analysis of 3, 4-diaminopyridine and 3-aminopyridine by density functional theory calculations. *Spectrochim. Acta Mol. Biomol. Spectrosc.* **76**, 502–512 (2010).
49. Antony, R. *et al.* Organic–inorganic hybrid catalysts containing new Schiff base for environment friendly cyclohexane oxidation. *RSC Adv.* **4**, 42816–42824 (2014).
50. Antony, R., Manickam, S. T. D., Saravanan, K., Karuppasamy, K. & Balakumar, S. Synthesis, spectroscopic and catalytic studies of Cu(II), Co(II) and Ni(II) complexes immobilized on Schiff base modified chitosan. *J. Mol. Struct.* **1050**, 53–60 (2013).
51. Raman, N., Jeyamurugan, R., Sudharsan, S., Karuppasamy, K. & Mitu, L. Metal based pharmacologically active agents: Synthesis, structural elucidation, DNA interaction, *in vitro* antimicrobial and *in vitro* cytotoxic screening of copper(II) and zinc(II) complexes derived from amino acid based pyrazolone derivatives. *Arab. J. Chem.* **6**, 235–247 (2013).
52. El-Ansary, A. L. & Abdel-Kader, N. S. Synthesis, characterization of La (III), Nd (III), and Er (III) complexes with Schiff bases derived from Benzopyran-4-one and their fluorescence study. *International Journal of Inorganic Chemistry* **2012** (2012).
53. Yan, Z.-Z., Tang, Y., Liu, W.-S., Cui, H.-X. & Tan, M.-Y. Synthesis and Luminescent Properties of Lanthanide Complexes with a Novel Multipodal Ligand. *J. Fluoresc.* **18**, 473–478, <https://doi.org/10.1007/s10895-007-0288-8> (2008).
54. Sinha, D. *et al.* Synthesis, characterization and biological activity of Schiff base analogues of indole-3-carboxaldehyde. *Eur. J. Med. Chem.* **43**, 160–165 (2008).
55. Adsule, S. *et al.* Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells. *J. Med. Chem.* **49**, 7242–7246 (2006).
56. Trimukhe, K. & Varma, A. Metal complexes of crosslinked chitosans: Correlations between metal ion complexation values and thermal properties. *Carbohydr. Polym.* **75**, 63–70 (2009).
57. Pavlovic, I. M., Draguta, S., Fokina, M. I., Timofeeva, T. V. & Denisjuk, I. Y. Synthesis, crystal growth, thermal and spectroscopic studies of acentric materials constructed from aminopyridines and 4-nitrophenol. *Opt. Commun.* **362**, 64–68 (2016).
58. Acton, A. A. *Issues in Materials and Manufacturing Research*. (ScholarlyEditions, 2011).
59. Beppu, M., Arruda, E., Vieira, R. & Santos, N. Adsorption of Cu(II) on porous chitosan membranes functionalized with histidine. *J. Membrane Sci.* **240**, 227–235 (2004).
60. Tirkistani, F. A. A. Thermal analysis of chitosan modified by cyclic oxygenated compounds. *Polym. Degrad. Stabil.* **61**, 161–164 (1998).
61. dos Santos, J. E., Dockal, E. & Cavalheiro, É. T. Thermal behavior of Schiff bases from chitosan. *J. Therm. Anal. Calorim.* **79**, 243–248 (2005).
62. Wang, M.-F. *et al.* Synthesis and crystal structure of a Schiff base derived from two similar pyrazolone rings and its rare earth complexes: DNA-binding and antioxidant activity. *J. Coord. Chem.* **65**, 3805–3820 (2012).
63. Thunus, L. & Lejeune, R. Overview of transition metal and lanthanide complexes as diagnostic tools. *Coord. Chem. Rev.* **184**, 125–155 (1999).
64. Kuz'min, V. *et al.* Investigation of anticancer activity of macrocyclic Schiff bases by means of 4D-QSAR based on simplex representation of molecular structure. *SAR QSAR Environ Res.* **16**, 219–230 (2005).
65. El-halim, H. F. A., Omar, M. & Mohamed, G. G. Synthesis, structural, thermal studies and biological activity of a tridentate Schiff base ligand and their transition metal complexes. *Spectrochim. Acta A* **78**, 36–44 (2011).
66. Ramade, I., Kahn, O., Jeannin, Y. & Robert, F. Design and Magnetic Properties of a Magnetically Isolated Gd<sup>III</sup>Cu<sup>II</sup> Pair. Crystal Structures of [Gd(hfa)<sub>3</sub>Cu(salen)], [Y(hfa)<sub>3</sub>Cu(salen)], [Gd(hfa)<sub>3</sub>Cu(salen)(Meim)], and [La(hfa)<sub>3</sub>(H<sub>2</sub>O)Cu(salen)] [hfa = Hexafluoroacetylacetonato, salen = N, N'-Ethylenebis (salicylideneaminato), Meim = 1-Methylimidazole]. *Inorg. Chem.* **36**, 930–936 (1997).
67. Jayabalakrishnan, C. & Natarajan, K. Ruthenium(II) carbonyl complexes with tridentate Schiff bases and their antibacterial activity. *Transit. Metal Chem.* **27**, 75–79 (2002).
68. Balashanmugam, P., Durai, P., Balakumaran, M. D. & Kalaichelvan, P. T. Phytosynthesized gold nanoparticles from *C. roxburghii* DC. leaf and their toxic effects on normal and cancer cell lines. *J. Photoch. Photobio. B* **165**, 163–173 (2016).

69. Parveen, A. & Rao, S. Cytotoxicity and Genotoxicity of Biosynthesized Gold and Silver Nanoparticles on Human Cancer Cell Lines. *J. Clust. Sci.* **26**, 775–788, <https://doi.org/10.1007/s10876-014-0744-y> (2015).
70. Li, G.-Y. *et al.* Synthesis, crystal structure, DNA interaction and anticancer activity of tridentate copper(II) complexes. *J. Inorg. Biochem.* **119**, 43–53 (2013).
71. Hussain, A. *et al.* Photocytotoxic lanthanum(III) and gadolinium(III) complexes of phenanthroline bases showing light-induced DNA cleavage activity. *Inorg. Chem.* **49**, 4036–4045 (2010).
72. Alaghaz, A.-N. M., Bayoumi, H. A., Ammar, Y. A. & Aldhlmani, S. A. Synthesis, characterization, and antipathogenic studies of some transition metal complexes with N, O-chelating Schiff's base ligand incorporating azo and sulfonamide Moieties. *J. Mol. Struct.* **1035**, 383–399 (2013).
73. Taylor, R. C., Cullen, S. P. & Martin, S. J. Apoptosis: controlled demolition at the cellular level. *Nat. Rev. Mol. Cell Biol.* **9**, 231–241 (2008).
74. Gou, Y. *et al.* Structure and biological properties of mixed-ligand Cu(II) Schiff base complexes as potential anticancer agents. *Eur. J. Med. Chem.* **134**, 207–217 (2017).
75. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J. Immunol. Methods* **65**, 55–63 (1983).
76. Bortner, C. D., Oldenburg, N. B. & Cidlowski, J. A. The role of DNA fragmentation in apoptosis. *Trends Cell Biol.* **5**, 21–26 (1995).

## Acknowledgements

This work was partly supported by the Ministry of Trade, Industry & Energy (MOTIE, Korea) under Sensor Industrial Technology Innovation Program (No. 10063682), the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2017R1D1A1A09000823), and the research program of Dongguk University in 2017.

## Author Contributions

K.A. initiated the study, performed the extensive experiments related to the growth of the samples and manuscript preparation with the assistance of co-authors. A.S. and K.K. participated in the data analyses and manuscript preparation. E.D., H.-S.K. and D.V. participation included planning, design experimental work, data analysis, discussion and manuscript preparation. All the authors read and approved the final manuscript.

## Additional Information

**Supplementary information** accompanies this paper at <https://doi.org/10.1038/s41598-018-21366-1>.

**Competing Interests:** The authors declare no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018